Captrust Financial Advisors Acquires Shares of 5,722 Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,722 shares of the company's stock, valued at approximately $514,000.

Other institutional investors also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. bought a new position in Axsome Therapeutics in the second quarter valued at about $27,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Axsome Therapeutics during the 2nd quarter worth approximately $47,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after acquiring an additional 318 shares during the last quarter. Moors & Cabot Inc. acquired a new position in Axsome Therapeutics in the 3rd quarter valued at approximately $200,000. Finally, Whalen Wealth Management Inc. bought a new position in shares of Axsome Therapeutics during the third quarter valued at $236,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Wells Fargo & Company initiated coverage on Axsome Therapeutics in a report on Tuesday, September 3rd. They issued an "overweight" rating and a $140.00 price objective for the company. Robert W. Baird increased their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Axsome Therapeutics in a research report on Monday, November 25th. StockNews.com upgraded Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $121.00 price target on shares of Axsome Therapeutics in a report on Thursday. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $125.93.

Axsome Therapeutics Stock Down 4.5 %

Shares of AXSM traded down $4.27 during trading hours on Friday, reaching $90.10. The stock had a trading volume of 581,575 shares, compared to its average volume of 610,712. The firm has a 50-day simple moving average of $93.02 and a 200 day simple moving average of $87.31. Axsome Therapeutics, Inc. has a 12 month low of $64.11 and a 12 month high of $105.00. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The company has a market capitalization of $4.37 billion, a price-to-earnings ratio of -13.80 and a beta of 1.18.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, beating analysts' consensus estimates of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period last year, the firm earned ($1.32) earnings per share. Equities research analysts predict that Axsome Therapeutics, Inc. will post -4.6 earnings per share for the current fiscal year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.